I-SPY 2: optimising cancer drug development in the 21st century

by Bartsch, Rupert, de Azambuja, Evandro
Published in ESMO Open (2016)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?

by Franzoi, Maria Alice, de Azambuja, Evandro
Published in ESMO Open (2020)

Threat posed by unproven drugs in medical oncology

by Pondé, Noam, Ades, Felipe, de Azambuja, Evandro
Published in ESMO Open (2016)

Phosphoethanolamine and the danger of unproven drugs

by Pondé, Noam, de Azambuja, Evandro, Ades, Felipe
Published in Ecancermedicalscience (2016)

Male breast cancer: finding the way in this uncommon path

by Maurer, Christian, Martel, Samuel, de Azambuja, Evandro
Published in ESMO Open (2017)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

by Poggio, Francesca, Lambertini, Matteo, de Azambuja, Evandro
Published in ESMO Open (2018)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

by Lambertini, Matteo, Viglietti, Giulia, de Azambuja, Evandro
Published in ESMO Open (2018)

How I treat metastatic triple-negative breast cancer

by Caparica, Rafael, Lambertini, Matteo, de Azambuja, Evandro
Published in ESMO Open (2019)

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer

by Eiger, Daniel, Brandão, Mariana, de Azambuja, Evandro
Published in ESMO Open (2020)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

by Agostinetto, Elisa, Caparica, Rafael, de Azambuja, Evandro
Published in ESMO Open (2020)

Twenty years of anti-HER2 therapy-associated cardiotoxicity

by Pondé, Noam F, Lambertini, Matteo, de Azambuja, Evandro
Published in ESMO Open (2016)

How Long is Enough – Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer

by Pinto, Ana Catarina, de Azambuja, Evandro, Piccart-Gebhart, Martine
Published 2013

Oncofertility counselling in premenopausal women with HER2-positive breast cancer

by Lambertini, Matteo, Demeestere, Isabelle, Viglietti, Giulia, de Azambuja, Evandro
Published in Oncotarget (2019)

The Exciting New Field of HER2-Low Breast Cancer Treatment

by Eiger, Daniel, Agostinetto, Elisa, Saúde-Conde, Rita, de Azambuja, Evandro
Published in Cancers (Basel) (2021)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

by Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Published 2009

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA

by Ades, Felipe, Senterre, Christelle, Zardavas, Dimitrios, de Azambuja, Evandro, Popescu, Razvan, Piccart, Martine
Published in PLoS One (2017)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

by Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Published in Onco Targets Ther (2017)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

by Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine
Published in Ther Adv Med Oncol (2019)

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer

by Curigliano, Giuseppe, de Azambuja, Evandro, Lenihan, Daniel, Calabrò, Maria Grazia, Cardinale, Daniela, Cipolla, Carlo Maria
Published in Oncologist (2019)

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

by Franzoi, Maria Alice, Saúde-Conde, Rita, Ferreira, Sofia Cristóvão, Eiger, Daniel, Awada, Ahmad, de Azambuja, Evandro
Published in Breast (2021)